title: Early change of thyroid hormone concentration after 131I treatment in patients with solitary toxic adenoma.
abstract: OBJECTIVE
  In spite of extensive use of 131I for treatment of hyperthyroidism, the results of early outcome are variable. In our prospective clinical study we tested whether 131I induced necrosis causing clinical aggravation of hyperthyroidism and increasing the free thyroid hormone concentration in the serum of patients with solitary toxic adenoma not pretreated with antithyroid drugs.
  
  
  METHODS
  30 consecutive patients were treated with 925 MBq 131I. Serum concentration of thyrotropin (TSH), free thyroxine (fT4), free triiodothyronine (fT3), thyroglobulin (Tg), and interleukin-6 (IL-6) were measured before and after application of 131I.
  
  
  RESULTS
  After application of 131I no clinical worsening was observed. FT4 and fT3 concentration did not change significantly within the first five days, whereas both of them significantly decreased after 12 days (p < 0.0001). Slight and clinically irrelevant increase in the level of the two thyroid hormones was observed in 9 patients. Furthermore, we observed a prolonged increase in Tg concentration and a transient increase in IL-6 concentration.
  
  
  CONCLUSIONS
  Neither evidence of any clinical aggravation of hyperthyroidism nor any significant increase in thyroid hormone concentration by 131I induced necrosis of thyroid cells was found. Therefore, the application of 131I may be considered as a safe and effective treatment for patients with hyperthyroidism due to toxic adenoma.
authors.affiliation: University Medical Centre Ljubljana, Department of Nuclear Medicine, Slovenia. edi.pirnat@kclj.si
authors.forename: E
authors.initials: E
authors.lastname: Pirnat
authors.forename: V
authors.initials: V
authors.lastname: Fidler
authors.forename: K
authors.initials: K
authors.lastname: Zaletel
authors.forename: S
authors.initials: S
authors.lastname: Gaberscek
authors.forename: S
authors.initials: S
authors.lastname: Hojker
mesh_terms: D000236:Adenoma / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D018450:Disease Progression; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013954:Thyroglobulin / Q000097:blood* / Q000528:radiation effects; D013964:Thyroid Neoplasms / Q000532:radiotherapy*; D013972:Thyrotropin / Q000097:blood*; D013974:Thyroxine / Q000097:blood*; D013997:Time Factors; D014284:Triiodothyronine / Q000097:blood*
chemical_list: D015850:Interleukin-6; D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D013972:Thyrotropin; D013954:Thyroglobulin; D013974:Thyroxine